268 related articles for article (PubMed ID: 17517377)
1. Discovery of Trp-Nle-Tyr-Met as a novel agonist for human formyl peptide receptor-like 1.
Wan HX; Zhou C; Zhang Y; Sun M; Wang X; Yu H; Yang X; Ye RD; Shen JK; Wang MW
Biochem Pharmacol; 2007 Jul; 74(2):317-26. PubMed ID: 17517377
[TBL] [Abstract][Full Text] [Related]
2. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
3. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils.
Bae YS; Park JC; He R; Ye RD; Kwak JY; Suh PG; Ho Ryu S
Mol Pharmacol; 2003 Sep; 64(3):721-30. PubMed ID: 12920210
[TBL] [Abstract][Full Text] [Related]
4. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.
Le Y; Gong W; Li B; Dunlop NM; Shen W; Su SB; Ye RD; Wang JM
J Immunol; 1999 Dec; 163(12):6777-84. PubMed ID: 10586077
[TBL] [Abstract][Full Text] [Related]
5. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling.
Lee HY; Lee SY; Shin EH; Kim SD; Kim JM; Lee MS; Ryu SH; Bae YS
Biochem Biophys Res Commun; 2007 Aug; 359(4):985-90. PubMed ID: 17577578
[TBL] [Abstract][Full Text] [Related]
6. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Fu H; Bylund J; Karlsson A; Pellmé S; Dahlgren C
Immunology; 2004 Jun; 112(2):201-10. PubMed ID: 15147563
[TBL] [Abstract][Full Text] [Related]
7. A novel nonpeptide ligand for formyl peptide receptor-like 1.
Nanamori M; Cheng X; Mei J; Sang H; Xuan Y; Zhou C; Wang MW; Ye RD
Mol Pharmacol; 2004 Nov; 66(5):1213-22. PubMed ID: 15308762
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1.
Zhou C; Zhang S; Nanamori M; Zhang Y; Liu Q; Li N; Sun M; Tian J; Ye PP; Cheng N; Ye RD; Wang MW
Mol Pharmacol; 2007 Oct; 72(4):976-83. PubMed ID: 17652444
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of formyl peptide receptor signaling by peptide ligands.
Bae YS; Song JY; Kim Y; He R; Ye RD; Kwak JY; Suh PG; Ryu SH
Mol Pharmacol; 2003 Oct; 64(4):841-7. PubMed ID: 14500740
[TBL] [Abstract][Full Text] [Related]
10. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
Dahlgren C; Christophe T; Boulay F; Madianos PN; Rabiet MJ; Karlsson A
Blood; 2000 Mar; 95(5):1810-8. PubMed ID: 10688842
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of formyl peptide receptor family in human NK cells.
Kim SD; Kim JM; Jo SH; Lee HY; Lee SY; Shim JW; Seo SK; Yun J; Bae YS
J Immunol; 2009 Nov; 183(9):5511-7. PubMed ID: 19843937
[TBL] [Abstract][Full Text] [Related]
12. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists.
Karlsson J; Fu H; Boulay F; Bylund J; Dahlgren C
Biochem Pharmacol; 2006 May; 71(10):1488-96. PubMed ID: 16549058
[TBL] [Abstract][Full Text] [Related]
13. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Christophe T; Karlsson A; Dugave C; Rabiet MJ; Boulay F; Dahlgren C
J Biol Chem; 2001 Jun; 276(24):21585-93. PubMed ID: 11285256
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of formyl peptide receptor-like 1 by peptide ligands.
Bae YS; Yi HJ; Lee HY; Jo EJ; Kim JI; Lee TG; Ye RD; Kwak JY; Ryu SH
J Immunol; 2003 Dec; 171(12):6807-13. PubMed ID: 14662886
[TBL] [Abstract][Full Text] [Related]
15. The chemoattractant Trp-Lys-Tyr-Met-Val-D-Met activates eosinophils through the formyl peptide receptor and one of its homologues, formyl peptide receptor-like 1.
Svensson L; Dahlgren C; Wennerås C
J Leukoc Biol; 2002 Oct; 72(4):810-8. PubMed ID: 12377951
[TBL] [Abstract][Full Text] [Related]
16. Changes in the ratio between FPR and FPRL1 triggered superoxide production in human neutrophils-a tool in analysing receptor specific events.
Fu H; Karlsson J; Björkman L; Stenfeldt AL; Karlsson A; Bylund J; Dahlgren C
J Immunol Methods; 2008 Feb; 331(1-2):50-8. PubMed ID: 18166194
[TBL] [Abstract][Full Text] [Related]
17. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.
Bae YS; Lee HY; Jo EJ; Kim JI; Kang HK; Ye RD; Kwak JY; Ryu SH
J Immunol; 2004 Jul; 173(1):607-14. PubMed ID: 15210823
[TBL] [Abstract][Full Text] [Related]
18. A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from Staphylococcus aureus (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR.
Prat C; Haas PJ; Bestebroer J; de Haas CJ; van Strijp JA; van Kessel KP
J Immunol; 2009 Nov; 183(10):6569-78. PubMed ID: 19846866
[TBL] [Abstract][Full Text] [Related]
19. Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis.
Le Y; Ye RD; Gong W; Li J; Iribarren P; Wang JM
FEBS J; 2005 Feb; 272(3):769-78. PubMed ID: 15670157
[TBL] [Abstract][Full Text] [Related]
20. A new insight into the role of "old" chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4.
Le Y; Shen W; Li B; Gong W; Dunlop NM; Wang JM
Forum (Genova); 1999; 9(4):299-314. PubMed ID: 10611407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
